Q3 FY2026 · ended Mar 31, 2026 · Revenue $0 · Filed May 14, 2026
Benitec Biopharma Inc. (BNTC) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$5.0 million. As of Jun 30, 2026 it held $180.0 million in cash and investments and $762,000 in total debt.
Revenue
$0
Net income
$-12.81M
-45.5% vs year-ago quarter
Operating cash flow
$-4.94M
+39.9% vs year-ago quarter
Free cash flow
$-5.02M
+38.9% vs year-ago quarter
EPS
$-0.26
-23.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
34.88M
+32.9% vs year-ago quarter
Net cash
$179.21M
Q4 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BNTC (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Hayward, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1808898
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q4 FY2026 Jun 30, 2026 |
Q3 FY2026 Mar 31, 2026 |
Q2 FY2026 Dec 31, 2025 |
Q1 FY2026 Sep 30, 2025 |
Q4 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | — |
| Operating income | -$14.4M | -$13.6M | -$13.4M | -$9.8M | -$9.8M |
| Net income | -$12.8M | -$11.9M | -$11.8M | -$9.0M | -$8.8M |
| Diluted EPS | -$0.26 | -$0.24 | -$0.26 | -$0.22 | -$0.21 |
| Operating cash flow | -$4.9M | -$4.5M | -$3.8M | -$3.4M | -$8.2M |
| Free cash flow | -$5.0M | -$4.5M | -$3.8M | — | -$8.2M |
| Total assets | $182.6M | $187.0M | $190.7M | $96.0M | $99.6M |
| Total liabilities | $5.6M | $3.7M | $3.3M | $2.4M | $2.3M |
| Stockholders' equity | $177.0M | $183.3M | $187.4M | $93.6M | $97.3M |
| Cash and investments | $180.0M | $184.8M | $188.8M | $94.5M | $97.7M |
| Total debt | $762,000 | $876,000 | $987,000 | $817,000 | $849,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 5, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Auditor change
|
Sep 30, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Auditor change
|
Sep 24, 2026 | Sep 18, 2026 |
| 10-K | Annual report | Sep 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Sep 14, 2026 | Sep 14, 2026 |
All 334 Benitec Biopharma Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.